Preclinical development of HIvax: Human survivin highly immunogenic vaccines

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 7, 2015, Pages 1585-1595

  Hoffmann, Peter R ^a   Panigada, Maddalena ^b   Soprana, Elisa ^b   Terry, Frances ^c   Bandar, Ivo Sah ^a   Napolitano, Andrea ^d   Rose, Aaron H ^a   Hoffmann, Fukun W ^a   Ndhlovu, Lishomwa C ^a   Belcaid, Mahdi ^e   Moise, Lenny ^f   Groot, Anne S De ^f   Carbone, Michele ^a,d   Gaudino, Giovanni ^d   Matsui, Takashi ^a   Siccardi, Antonio ^b   Bertino, Pietro ^a  

^a UNIVERSITY OF HAWAII   (United States)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c EpiVax Inc   (United States)

^d UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^e UNIVERSITY OF HAWAII   (United States)

^f UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Cancer vaccines; EpiMatrix; Fowlpox; Immunodominant epitopes; Mesothelioma; T Lymphocytes; Tregitopes

Indexed keywords

GAMMA INTERFERON; GRANZYME B; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; POXVIRUS VECTOR; SURVIVIN; BIRC5 PROTEIN, HUMAN; CANCER VACCINE; EPITOPE; GRANZYME; INHIBITOR OF APOPTOSIS PROTEIN;

ARTICLE; BINDING AFFINITY; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; FLOW CYTOMETRY; HAPLOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HLA TYPING; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; MESOTHELIOMA; PEPTIDE SYNTHESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; T LYMPHOCYTE; TRANSGENE; ANTIBODY PRODUCTION; CELL CULTURE; CYTOTOXIC T LYMPHOCYTE; GENE VECTOR; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; LYMPHOCYTE ACTIVATION; REGULATORY T LYMPHOCYTE; SECRETION (PROCESS); TUMOR CELL LINE;

ANTIBODY FORMATION; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELLS, CULTURED; DENDRITIC CELLS; GENETIC VECTORS; GRANZYMES; HUMANS; IMMUNIZATION; IMMUNODOMINANT EPITOPES; INHIBITOR OF APOPTOSIS PROTEINS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MESOTHELIOMA; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TRANSGENES;

EID: 84944452759     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1050572     Document Type: Article

References (42)

1. Melief CJ, Kast WM. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol Rev 1995; 145:167-77; PMID:7590825; http://dx. doi. org/10. 1111/j. 1600-065X. 1995. tb00081. x.
2. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998; 188:2357-68; PMID:9858522; http://dx. doi. org/10. 1084/jem. 188. 12. 2357.
3. Oka Y, Tsuboi A, Elisseeva OA, Nakajima H, Fujiki F, Kawakami M, Shirakata T, Nishida S, Hosen N, Oji Y, et al. WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers. Sci World J 2007; 7:649-65; PMID:17619750; http://dx. doi. org/10. 1100/tsw. 2007. 119.
4. Hazama S, Nakamura Y, Takenouchi H, Suzuki N, Tsunedomi R, Inoue Y, Tokuhisa Y, Iizuka N, Yoshino S, Takeda K, et al. A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome. J Transl Med 2014; 12:63; PMID:24612787; http://dx. doi. org/10. 1186/ 1479-5876-12-63.
5. Lennerz V, Gross S, Gallerani E, Sessa C, Mach N, Boehm S, Hess D, von Boehmer L, Knuth A, Ochsenbein AF, et al. Immunologic response to the survivinderived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunol Immunother 2014; 63:381-94; PMID:24487961; http://dx. doi. org/10. 1007/s00262-013-1516-5.
6. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3:917-21; PMID:9256286; http://dx. doi. org/10. 1038/nm0897-917.
7. Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, Lal A, Wang CJ, Beaudry GA, Ciriello KM, et al. Analysis of human transcriptomes. Nat Genet 1999; 23:387-8; PMID:10581018; http://dx. doi. org/ 10. 1038/70487.
8. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 1999; 113:1076- 81; PMID:10594755; http://dx. doi. org/10. 1046/ j. 1523-1747. 1999. 00776. x.
9. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003; 22:8581-9; PMID:14634620; http://dx. doi. org/ 10. 1038/sj. onc. 1207113.
10. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 1999; 341:452-3; PMID:10438269; http://dx. doi. org/10. 1056/NEJM199908053410614.
11. Rohayem J, Diestelkoetter P, Weigle B, Oehmichen A, Schmitz M, Mehlhorn J, Conrad K, Rieber EP. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res 2000; 60:1815-7; PMID:10766164.
12. AndersenMH, Pedersen LO, Becker JC, Straten PT. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res 2001; 61:869-72; PMID:11221872.
13. Casati C, Dalerba P, Rivoltini L, Gallino G, Deho P, Rini F, Belli F, Mezzanzanica D, Costa A, Andreola S, et al. The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. Cancer Res 2003; 63:4507-15; PMID:12907624.
14. Schmitz M, Diestelkoetter P, Weigle B, Schmachtenberg F, Stevanovic S, Ockert D, Rammensee HG, Rieber EP. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 2000; 60:4845-9; PMID:10987296.
15. Karanikas V, Soukou F, Kalala F, Kerenidi T, Grammoustianou ES, Gourgoulianis KI, Germenis AE. Baseline levels of CD8+ T cells against survivin and survivin-2B in the blood of lung cancer patients and cancer-free individuals. Clin Immunol 2008; 129:230- 40; PMID:18789878; http://dx. doi. org/10. 1016/j. clim. 2008. 07. 024.
16. Reker S, Meier A, Holten-Andersen L, Svane IM, Becker JC, thor Straten P, Andersen MH. Identification of novel survivin-derived CTL epitopes. Cancer Biol Ther 2004; 3:173-9; PMID:14726703; http://dx. doi. org/10. 4161/cbt. 3. 2. 611.
17. Bertino P, Panigada M, Soprana E, Bianchi V, Bertilaccio S, Sanvito F, Rose AH, Yang H, Gaudino G, Hoffmann PR, et al. Fowlpox-based survivin vaccination for malignant mesothelioma therapy. Int J Cancer 2013; 133:612-23; PMID:23335100; http://dx. doi. org/10. 1002/ijc. 28048.
18. Kleinberg L, Lie AK, Florenes VA, Nesland JM, Davidson B. Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma. Hum Pathol 2007; 38:986-94; PMID:17350081; http://dx. doi. org/10. 1016/j. humpath. 2006. 12. 013.
19. Gregory SH, Mott S, Phung J, Lee J, Moise L, McMurry JA, Martin W, De Groot AS. Epitope-based vaccination against pneumonic tularemia. Vaccine 2009; 27:5299-306; PMID:19616492; http://dx. doi. org/10. 1016/j. vaccine. 2009. 06. 101.
20. McMurry JA, Gregory SH, Moise L, Rivera D, Buus S, De Groot AS. Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine. Vaccine 2007; 25:3179-91; PMID:17291638; http://dx. doi. org/10. 1016/j. vaccine. 2007. 01. 039.
21. Moise L, Buller RM, Schriewer J, Lee J, Frey SE, Weiner DB, Martin W, De Groot AS. VennVax, a DNAprime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone. Vaccine 2011; 29:501-11; PMID:21055490; http://dx. doi. org/ 10. 1016/j. vaccine. 2010. 10. 064.
22. Moss SF, Moise L, Lee DS, Kim W, Zhang S, Lee J, Rogers AB, Martin W, De Groot AS. HelicoVax: epitope- based therapeutic Helicobacter pylori vaccination in a mouse model. Vaccine 2011; 29:2085-91; PMID:21236233; http://dx. doi. org/10. 1016/j. vaccine. 2010. 12. 130.
23. Lladser A, Ljungberg K, Tufvesson H, Tazzari M, Roos AK, Quest AF, Kiessling R. Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma. Cancer Immunol Immunother 2010; 59:81- 92; PMID:19526360; http://dx. doi. org/10. 1007/ s00262-009-0725-4.
24. Andersen MH, Soerensen RB, Becker JC, thor Straten P. HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer. J Transl Med 2006; 4:38; PMID:16948867; http://dx. doi. org/10. 1186/1479- 5876-4-38.
25. Wang QM, Sun SH, Hu ZL, Zhou FJ, Yin M, Xiao CJ, Zhang JC. Epitope DNA vaccines against tuberculosis: spacers and ubiquitin modulates cellular immune responses elicited by epitope DNA vaccine. Scand J Immunol 2004; 60:219-25; PMID:15320877; http:// dx. doi. org/10. 1111/j. 0300-9475. 2004. 01442. x.
26. Turnquist HR, Vargas SE, McIlhaney MM, Li S, Wang P, Solheim JC. Calreticulin binds to the alpha1 domain of MHC class I independently of tapasin. Tissue Antigens 2002; 59:18-24; PMID:11972874; http://dx. doi. org/10. 1034/j. 1399-0039. 2002. 590104. x.
27. Livingston B, Crimi C, Newman M, Higashimoto Y, Appella E, Sidney J, Sette A. A rational strategy to design multiepitope immunogens based on multiple Thlymphocyte epitopes. J Immunol 2002; 168:5499-506; http://dx. doi. org/10. 4049/jimmunol. 168. 11. 5499.
28. Cousens LP, Su Y, McClaine E, Li X, Terry F, Smith R, Lee J, Martin W, Scott DW, De Groot AS. Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes. J Diabetes Res 2013; 2013:621693; PMID:23710469; http://dx. doi. org/ 10. 1155/2013/621693.
29. De Groot AS. Do Tregitopes have the potential to impact the current treatment landscape of autoimmune diseases? Expert Rev Clin Immunol 2013; 9:1155-7; PMID:24215404; http://dx. doi. org/10. 1586/ 1744666X. 2013. 858602.
30. Su Y, Rossi R, De Groot AS, Scott DW. Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se. J Leukoc Biol 2013; 94:377-83; PMID:23729499; http://dx. doi. org/ 10. 1189/jlb. 0912441.
31. Nezafat N, Ghasemi Y, Javadi G, Khoshnoud MJ, Omidinia E. A novel multi-epitope peptide vaccine against cancer: an in silico approach. J Theor Biol 2014; 349:121-34; PMID:24512916; http://dx. doi. org/10. 1016/j. jtbi. 2014. 01. 018.
32. Thiele F, Tao S, Zhang Y, Muschaweckh A, Zollmann T, Protzer U, Abele R, Drexler I. Modified Vaccinia Virus Ankara-Infected Dendritic Cells Present CD4+ T-Cell Epitopes by Endogenous Major Histocompatibility Complex Class II Presentation Pathways. J Virol 2015; 89:2698-709; PMID:25520512; http://dx. doi. org/10. 1128/JVI. 03244-14.
33. Jaraquemada D, Marti M, Long EO. An endogenous processing pathway in vaccinia virus-infected cells for presentation of cytoplasmic antigens to class II-restricted T cells. J Exp Med 1990; 172:947-54; PMID:2388037; http://dx. doi. org/10. 1084/jem. 172. 3. 947.
34. Nuchtern JG, Biddison WE, Klausner RD. Class II MHC molecules can use the endogenous pathway of antigen presentation. Nature 1990; 343:74-6; PMID:1967486; http://dx. doi. org/10. 1038/ 343074a0.
35. Chen JL, Dawoodji A, Tarlton A, Gnjatic S, Tajar A, Karydis I, Browning J, Pratap S, Verfaille C, Venhaus RR, et al. NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO- 1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus. Int J Cancer 2014; 136(6):E590-601.
36. Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech- Fauceglia P, Miller A, Beck A, Morrison CD, Ritter G, Godoy H, et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A 2012; 109:5797- 802; PMID:22454499; http://dx. doi. org/10. 1073/ pnas. 1117208109.
37. Cohen T, Moise L, Ardito M, Martin W, De Groot AS. A method for individualizing the prediction of immunogenicity of protein vaccines and biologic therapeutics: individualized T cell epitope measure (iTEM). J Biomed Biotechnol 2010; 2010; PMID:20706613.
38. Pass HI, Stevens EJ, Oie H, Tsokos MG, Abati AD, Fetsch PA, Mew DJ, Pogrebniak HW, Matthews WJ. Characteristics of nine newly derived mesothelioma cell lines. Ann Thorac Surg 1995; 59:835-44; PMID:7695406; http://dx. doi. org/10. 1016/0003- 4975(95)00045-M.
39. Di Lullo G, Soprana E, Panigada M, Palini A, Agresti A, Comunian C, Milani A, Capua I, Erfle V, Siccardi AG. The combination of marker gene swapping and fluorescence-activated cell sorting improves the efficiency of recombinant modified vaccinia virus Ankara vaccine production for human use. J Virol Methods 2010; 163:195-204; PMID:19778556; http://dx. doi. org/10. 1016/j. jviromet. 2009. 09. 016.
40. Soprana E, Panigada M, Knauf M, Radaelli A, Vigevani L, Palini A, Villa C, Malnati M, Cassina G, Kurth R, et al. Joint production of prime/boost pairs of Fowlpox Virus and Modified Vaccinia Ankara recombinants carrying the same transgene. J Virol Methods 2011; 174:22-8; PMID:21419167; http://dx. doi. org/ 10. 1016/j. jviromet. 2011. 03. 013.
41. Robinson J, Mistry K, McWilliam H, Lopez R, Parham P, Marsh SG. The IMGT/HLA database. Nucleic Acids Res 2011; 39:D1171-6; PMID:21071412; http://dx. doi. org/10. 1093/nar/gkq998.
42. Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 2010; 26:2460-1; PMID:20709691; http://dx. doi. org/10. 1093/ bioinformatics/btq461.